Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 177 shares. Based on an average daily trading volume, of 4,062 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Santen Pharmaceutical Stock Performance

Shares of OTCMKTS SNPHY remained flat at $10.54 during mid-day trading on Wednesday. The stock had a trading volume of 1,995 shares, compared to its average volume of 2,619. The company’s fifty day moving average is $11.67 and its two-hundred day moving average is $11.73. Santen Pharmaceutical has a fifty-two week low of $9.22 and a fifty-two week high of $13.93.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and commercializes prescription eye-care medicines and related products for conditions affecting vision and ocular health.

Its portfolio includes treatments for glaucoma and ocular hypertension, dry eye disease, retinal disorders, eye infections and allergies, as well as other ophthalmic conditions. Santen also conducts research in areas such as regenerative medicine and other therapies intended to address unmet needs in eye care.

Founded in Japan in 1890, Santen has expanded beyond its domestic market and serves patients and healthcare professionals across Asia, Europe and other international markets.